Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1

4(50.0%)

Phase 1

3(37.5%)

N/A

1(12.5%)

8Total

Early Phase 1(4)

Phase 1(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06643910Not ApplicableNot Yet Recruiting

A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer

Role: lead

NCT06645301Early Phase 1Not Yet Recruiting

BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies

Role: lead

NCT06645314Early Phase 1Not Yet Recruiting

Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma

Role: lead

NCT06526832Phase 1Unknown

A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer

Role: lead

NCT05864924Phase 1Completed

A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

Role: lead

NCT06173726Early Phase 1Not Yet Recruiting

Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer

Role: lead

NCT06152757Early Phase 1Recruiting

BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors

Role: lead

NCT03736122Phase 1Unknown

A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites

Role: lead

All 8 trials loaded